- Home
- DCI vs LEGN Comparison
DCI vs LEGN Comparison
Compare DCI & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DCI
- LEGN
- Stock Information
- Founded
- DCI 1915
- LEGN 2014
- Country
- DCI United States
- LEGN United States
- Employees
- DCI N/A
- LEGN N/A
- Industry
- DCI Pollution Control Equipment
- LEGN Biotechnology: Pharmaceutical Preparations
- Sector
- DCI Industrials
- LEGN Health Care
- Exchange
- DCI Nasdaq
- LEGN Nasdaq
- Market Cap
- DCI 7.9B
- LEGN 6.7B
- IPO Year
- DCI 1987
- LEGN 2020
- Fundamental
- Price
- DCI $80.88
- LEGN $33.11
- Analyst Decision
- DCI Hold
- LEGN Strong Buy
- Analyst Count
- DCI 3
- LEGN 12
- Target Price
- DCI $80.33
- LEGN $73.36
- AVG Volume (30 Days)
- DCI 752.1K
- LEGN 1.1M
- Earning Date
- DCI 08-27-2025
- LEGN 11-11-2025
- Dividend Yield
- DCI 1.48%
- LEGN N/A
- EPS Growth
- DCI N/A
- LEGN N/A
- EPS
- DCI 3.05
- LEGN N/A
- Revenue
- DCI $3,690,900,000.00
- LEGN $796,838,000.00
- Revenue This Year
- DCI $3.77
- LEGN $70.75
- Revenue Next Year
- DCI $5.12
- LEGN $52.47
- P/E Ratio
- DCI $26.61
- LEGN N/A
- Revenue Growth
- DCI 2.92
- LEGN 74.75
- 52 Week Low
- DCI $57.45
- LEGN $27.34
- 52 Week High
- DCI $83.31
- LEGN $52.31
- Technical
- Relative Strength Index (RSI)
- DCI 64.62
- LEGN 36.16
- Support Level
- DCI $79.74
- LEGN $33.20
- Resistance Level
- DCI $81.66
- LEGN $34.71
- Average True Range (ATR)
- DCI 1.82
- LEGN 1.22
- MACD
- DCI 0.04
- LEGN -0.09
- Stochastic Oscillator
- DCI 69.74
- LEGN 10.96
About DCI Donaldson Company Inc.
Donaldson is a leading manufacturer of filtration systems and replacement parts (including air filtration systems, liquid filtration systems, and dust, fume, and mist collectors). The company serves a diverse range of end markets, including construction, mining, agriculture, truck, and industrial. Its business is organized into three segments: mobile solutions, industrial solutions, and life sciences. Donaldson generated approximately $3.6 billion in revenue and $544 million in operating income in its fiscal 2024.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.